



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@sequent.in

Website: www.sequent.in

CIN: L99999TS1985PLC196357

February 05, 2026

To,

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051

Scrip code: 512529

Symbol: VIYASH

Subject: Press Release for Q3 FY 2025-26

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Press Release on Unaudited Standalone and Consolidated Financial Results for the quarter ended December 31, 2025.

This is for your information and appropriate dissemination.

You are requested to take the same on record.

Yours faithfully,

For Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Yoshita Vora

Company Secretary & Compliance Officer

Encl: A/a



Viyash Scientific Limited

(Formerly known as SeQuent Scientific Limited)

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@sequent.in

Website: www.sequent.in CIN: L99999TS1985PLC196357

Post merger growth momentum continues in revenue and profitability Company to build Companion animal portfolio & CDMO services

Highlights

Q3 FY26 – Revenues at ₹ 8584 Million up by 10.9%, EBITDA* at ₹ 1854 Million up 64.4 %



9 Month FY26 – Revenues at ₹ 25004 Million up by 11.9%, EBITDA* at ₹ 5,024 Million up 58 %



Q3 FY 26 PAT up 15.5 % (including exceptional merger related costs)



9 Month FY 26 PAT up by 230%



Pre closure of high-cost Debt. Net Debt / EBITDA at 0.38 x



Mumbai, February 5, 2026

Viyash Scientific Limited (formerly SeQuent Scientific Limited), which has businesses across Formulations, APIs and CDMO Services for Human and Animal health, today announced its financial results for the quarter ended December 31, 2025. This is the first quarter where the results of the merged entity are being presented on a combined basis.



Consolidated Financial Highlights

₹ in millions

	Q3FY26	Q3FY25	Growth %	9-month FY26	9-month FY25	Growth %
Revenues	8,584	7,740	10.9%	25,004	22,345	11.9%
EBITDA*	1,854	1,127	64.4%	5,024	3,179	58%
EBITDA* %	21.6%	14.6%		20.1%	14.2%	
PAT	485 **	420	15.5%	1583	480	230%

EBITDA* refers to EBITDA excluding ESOP costs

**After including exceptional costs of Rs 413 mn on account of merger related expenses and one time MAT credit of reversal of Rs 77 mn

Detailed presentation on the performance forms part of this press release.

Commenting on the Company's performance, **Dr Hari Babu Bodepudi, Managing Director and Group CEO** stated

"We mark a significant milestone today, announcing results of the merged entity for first time. The results of Q3FY25-26 are an indication of the actions we have taken and the momentum we have built across the last few quarters, working as one team. Revenue, margins, profitability all have continued to show strong growth on the back of new product introductions, cost improvement and synergies across our business units. We have a strong balance sheet and market position and are geared up for capturing the market opportunity in the next 3-5 years. The merger is starting to generate benefits across R&D, manufacturing and front-end, all of which make us very excited for the journey ahead."



Earnings Call with Investors

The Company will conduct an Earnings call at **17:30 IST on February 06, 2025** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**

About Viyash Scientific Limited

Viyash Scientific Limited (formerly known as Sequent Scientific Limited) is headquartered in India, the Group is among top 25 Animal Health companies in the world. With over 3000 talented employees, Viyash Scientific Limited is an integrated pharmaceutical company having a rich portfolio of formulations and APIs for human and veterinary use, serving customers in over 100 countries. Viyash and its subsidiaries have manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and USA, with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc.

For details, feel free to contact

Yoshita Vora

Company Secretary, Tel: +91 22 4111 4717
investorrelations@sequent.in

Abhishek Singhal

Investor Relations Consultants
abhishek@arunya.co.in

Registered Office

3rd Floor, Srivalli's Corporate,
Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills,
Shaikpet, Hyderabad-500033, Telangana
CIN: L99999TS1985PLC196357
BSE Code: 512529 I NSE: SEQUENT
ISIN: INE807F01027 I REUTERS: EQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be responsible in any way for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances